Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2 (2022)

Peer-Reviewed Study · Pires L, Wilson BC, Bremner R, et al. · August 24, 2022

Pires L et al., 2022-08-24: Proof-of-principle clinical trial of nasal methylene blue photodynamic disinfection in COVID-19, reporting reduced viral infectivity in nasal swabs. A small clinical study, not a photobiomodulation study.

However, the viral infectivity in clinical nares swabs was reduced in 90% of samples and undetectable in 70% of samples. This is the first demonstration based on quantitative clinical viral infectivity measurements that MB-aPDT is a safe, easily delivered and effective front-line technique that can reduce local SARS-CoV-2 viral load.

Pires L et al., 2022-08-24: Proof-of-principle clinical trial of nasal methylene blue photodynamic disinfection in COVID-19, reporting reduced viral infectivity in nasal swabs. A small clinical study, not a photobiomodulation study. Study type: in vitro work plus proof-of-principle clinical trial. N not stated in abstract. Country: Canada (Toronto). MB-aPDT of the nares with non-thermal light; wavelength and dose not in abstract. Funding: not stated. Conflicts: none declared. Comparator: pre-treatment swabs. Endpoint infectivity, not symptoms. Study type: uncontrolled series.